LJPC stock forecast
Our latest prediction for La Jolla Pharmaceutical Co.'s stock price was made on the Jan. 13, 2020 when the stock price was at 7.00$.
In the short term (2weeks), LJPC's stock price should underperform the market by -2.42%. During that period the price should oscillate between -12.02% and +26.79%.
In the medium term (3months), LJPC's stock price should underperform the market by -9.62%. During that period the price should oscillate between -42.44% and +39.38%.Get email alerts
About La Jolla Pharmaceutical Co.
La Jolla Pharmaceutical Co. operates as a biopharmaceutical company, which engages in the discovery, development and commercialization of therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases. Its products includes LJPC-501, LJPC-401 and LJPC-0118. LJPC-501 is the proprietary formulation for angiotensin II. The LJPC-401 is the formulation of hepcidin, which is an endogenous peptide hormone and LJPC-0118 is La Jolla's investigational product for the treatment of severe malaria. The company was founded in 1989 and is headquartered in San Diego, CA.
At the moment the company generates 20M USD in revenues.
On its last earning announcement, the company reported a loss of -5.07$ per share.
The book value per share is 4.16$
Three months stock forecastJan. 13, 2020
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|